Cingulate Inc — Cash Flow (NASDAQ:CING)

Financials

Cash from operating activities -10.43 M-15.88 M-15.03 M-18.45 M-17.25 M -17.25 M Cash from investing activities -814.74 K-152.65 K-224.1 K-211.8 K-162.14 K -162.14 K Cash from financing activities 26.54 M4.9 M9.95 M30.82 M16.15 M 16.15 M Free cash flow -11.25 M-16.04 M-15.26 M-18.66 M-17.41 M -17.41 M

News

Cingulate increases at-the-market offering limit to $31.9 million

Cingulate reinstates Shane Schaffer as CEO, updates employment terms

Cingulate appoints new CCO, secures $6 million financing

Cingulate’s ADHD drug meets primary endpoints in phase 3 trial

FDA accepts Cingulate’s ADHD drug application, sets May 2026 target date

Cingulate secures manufacturing deal with Bend Bio Sciences for ADHD drug

Cingulate issues shares to lender in series of unregistered transactions

Cingulate appoints John A. Roberts as executive chairman, CEO placed on leave

Ascendiant Capital raises Cingulate stock price target to $62 from $61

Cingulate Posts Wider Loss in Q2

Cingulate places CEO on leave, appoints interim leadership

Cingulate submits NDA for ADHD treatment to FDA